WHO ICTRP trial
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
LBCTR2022035001 · Lebanon Clinical Trials Registry (LBCTR) · Not Recruiting
Key facts
| Trial ID | LBCTR2022035001 |
|---|---|
| Public title | Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients |
| Scientific title | A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients |
| Primary sponsor | Novartis Pharmaceuticals |
| Registry | Lebanon Clinical Trials Registry (LBCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 1 to 2 |
| Countries | Australia;Belgium;Canada;Denmark;Germany;Hungary;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;Lebanon |
| Conditions | Myelofibrosis Myelofibrosis;D75.8;Myelofibrosis |
| Interventions | - Drug: Ruxolitinib 5 mg tablets for oral use Other Name: INC424, Jakavi - Drug: Siremadlin 10 mg, 20 mg, or 40 mg capsules for oral use Other Name: HDM201 - Drug: Crizanlizumab 100 mg/mL concentrate for infusion for intravenous use Other… |
| Registration date | Dec 8, 2022 |
| Target size | 4 |
| Secondary IDs | NCT04097821 |
| Registry page | lbctr.moph.gov.lb |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: